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Anaphylaxis	is	a	life-threatening	hyperacute	immediate	hypersensitivity	reaction.	Classically,	it	depends	on	
IgE,	FcεRI,	mast	cells,	and	histamine.	However,	anaphylaxis	can	also	be	induced	by	IgG	antibodies,	and	an	
IgG1-induced	passive	type	of	systemic	anaphylaxis	has	been	reported	to	depend	on	basophils.	In	addition,	it	
was	found	that	neither	mast	cells	nor	basophils	were	required	in	mouse	models	of	active	systemic	anaphylaxis.	
Therefore,	we	investigated	what	antibodies,	receptors,	and	cells	are	involved	in	active	systemic	anaphylaxis	
in	mice.	We	found	that	IgG	antibodies,	FcγRIIIA	and	FcγRIV,	platelet-activating	factor,	neutrophils,	and,	to	a	
lesser	extent,	basophils	were	involved.	Neutrophil	activation	could	be	monitored	in	vivo	during	anaphylaxis.	
Neutrophil	depletion	inhibited	active,	and	also	passive,	systemic	anaphylaxis.	Importantly,	mouse	and	human	
neutrophils	each	restored	anaphylaxis	in	anaphylaxis-resistant	mice,	demonstrating	that	neutrophils	are	suffi-
cient	to	induce	anaphylaxis	in	mice	and	suggesting	that	neutrophils	can	contribute	to	anaphylaxis	in	humans.	
Our	results	therefore	reveal	an	unexpected	role	for	IgG,	IgG	receptors,	and	neutrophils	in	anaphylaxis	in	mice.	
These	molecules	and	cells	could	be	potential	new	targets	for	the	development	of	anaphylaxis	therapeutics	if	
the	same	mechanism	is	responsible	for	anaphylaxis	in	humans.
Introduction
Anaphylaxis is a systemic hyperacute allergic reaction (1) responsi-
ble for more than 1,500 deaths per year in the US (2). Anaphylaxis 
is associated with intense vasodilatation and bronchoconstriction, 
severe laryngeal edema, drop of cardiac pressure, and hypother-
mia. As anaphylaxis is a life-threatening medical emergency, the 
mechanisms thought to be responsible for anaphylaxis have been 
mostly investigated in animal models. Two types of models have 
been developed since the initial description of anaphylaxis in dogs 
(3): active anaphylaxis, in immunized animals, and passive anaphy-
laxis, in nonimmunized animals injected with antibodies. Indeed, 
susceptibility to anaphylaxis can be transferred by serum from 
immunized donors or by purified antibodies.
IgE-induced passive systemic anaphylaxis (PSA) is elicited by 
injecting mice systemically with IgE antibodies 24–48 hours 
before an i.v. challenge with specific antigen. The anaphylac-
tic shock that develops within minutes can be easily assessed 
by monitoring the decrease in body temperature. IgE-induced 
PSA observed in WT mice was abrogated in mice deficient for 
FcεRI, the high-affinity IgE receptor expressed by mast cells and 
basophils (4), and in mast cell–deficient W/Wv mice (5). It was 
also abrogated in histidine decarboxylase–deficient mice, which 
lack histamine (6), and in mice injected with histamine recep-
tor antagonists (7). Anaphylactic symptoms could be induced by 
an i.v. injection of histamine (6). These findings together dem-
onstrate the mandatory role of mast cells and of FcεRI in IgE-
induced PSA, and they emphasize the contribution of histamine, 
contained in mast cell granules that are rapidly released during 
exocytosis. This mechanism has been widely accepted as a para-
digm of the anaphylactic reaction.
IgG-induced PSA is elicited by injecting mice systemically with 
IgG antibodies 2–3 hours before an i.v. challenge with specific anti-
gen. Alternatively, preformed IgG immune complexes (IC) can be 
injected i.v. Similar symptoms develop, with comparable kinetics, 
during IgE- and IgG-induced PSA. IgG1 is the dominant antibody 
subclass raised during humoral responses to protein antigens in 
mice, and passively administered IgG1-IC are sufficient to induce 
anaphylaxis. Because the low-affinity IgG receptor FcγRIIIA was 
shown to trigger mast cell activation in vitro (8) and passive cuta-
neous anaphylaxis in vivo (9), it has been generally accepted that 
these receptors account for IgG1-induced PSA. No published 
paper formally demonstrated this assumption, but we confirmed 
that, indeed, IgG1-induced PSA was abrogated in FcγRIIIA-defi-
cient mice (P. Bruhns and M. Daëron, unpublished observations). 
Surprisingly, IgG1-induced PSA was not abrogated in mast cell–
deficient mice (5), but it was reported to be abrogated in basophil-
depleted mice (10). This suggests that mouse basophils express 
FcγRIIIA. FcγRIIIA are also expressed by other myeloid cells. 
Upon activation, mouse basophils rapidly release granular media-
tors, including histamine, but also lipid-derived mediators such 
as platelet-activating factor (PAF). Like histamine, PAF could, by 
itself, reproduce the clinical signs of an anaphylactic shock when 
injected in animals (11). PAF, but not histamine, was shown to be 
responsible for IgG1-induced PSA (10). These findings together 
indicate that IgG1-IC trigger anaphylaxis through the release of 
PAF, probably by aggregating FcγRIIIA on basophils.
Active systemic anaphylaxis (ASA) is elicited by an i.v. injection 
of antigen into mice immunized with that antigen. Similar symp-
toms develop with comparable kinetics during ASA and PSA in 
WT mice. More mice, however, die during ASA than during PSA. 
Different adjuvants can be used for immunization. It is generally 
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accepted that alum favors IgG1 and IgE antibodies, whereas CFA 
favors IgG2 antibodies. In both cases, however, IgG1 antibodies are 
the most abundant and IgE the less abundant. ASA was not affect-
ed in Cε-deficient mice, which produce no IgE (12). Antibodies 
other than IgE are therefore sufficient to induce ASA. Supporting 
this conclusion, ASA was not altered in FcεRI-deficient mice, but it 
was abrogated in FcRγ-deficient mice (5), which express no activat-
ing receptors for IgE (FcεRI) or for IgG (FcγRI, FcγRIIIA, FcγRIV). 
Activating FcRs are therefore mandatory for ASA. ASA was not 
altered in mast cell–deficient Wsh/Wsh or W/Wv mice (5, 13), 
in basophil-deficient mice (14), or in basophil-depleted WT mice 
(10). Neither mast cells nor basophils are therefore mandatory for 
ASA. Furthermore, ASA-induced decrease in body temperature 
still occurred in the absence of both cell types, but ASA-associated 
mortality was abolished (10). Basophils and mast cells can there-
fore contribute to ASA. Reduced anaphylactic shock was observed 
in PAF receptor–deficient (PAF-R–deficient) mice (15) and in mice 
injected with PAF-R antagonists (16). These findings together 
indicate that antibodies other than IgE, activating FcRs other than 
FcεRI, cell types other than basophils and mast cells, and media-
tors other than histamine contribute to ASA. These antibodies, 
FcRs, cells, and mediators are unknown.
We unravel here an unexpected role of neutrophils and an under-
estimated contribution of IgG and IgG receptors to anaphylaxis. 
Neutrophils and basophils both contributed to ASA in WT mice. 
Neutrophils, however, were sufficient for ASA in genetically modi-
fied mice expressing no activating IgG or IgE receptors on mast 
cells and basophils. Importantly, like murine neutrophils, human 
neutrophils restored ASA in ASA-resistant mice, suggesting that 
these cells can contribute to anaphylaxis in humans. Neutrophil-
dependent ASA was mediated by PAF. Neutrophils contributed 
also to IgG-induced PSA. Finally, 2 IgG receptors, FcγRIIIA and 
FcγRIV, accounted for ASA in WT mice.
Results
FcγRIV can trigger ASA. An i.v. antigen challenge induced a decrease of 
body temperature in WT or in mast cell–deficient Wsh mice immu-
nized with antigen in CFA/incomplete Freund adjuvant (IFA), but not 
in FcRγ–/– (officially referred to as Fcer1g–/–) mice, which lack all acti-
vating IgG and IgE receptors (data not shown). ASA indeed depends 
on antibodies. Immunizations in CFA/IFA lead to the production of 
comparable IgG1 and IgG2 antibody levels in WT and FcRγ–/– mice 
and, as expected (5), of higher levels of IgE antibodies in FcRγ–/– mice 
than in WT mice (Supplemental Figure 1A; supplemental material 
available online with this article; doi:10.1172/JCI45232DS1). Non-
immunized WT, but not FcRγ–/–, mice underwent anaphylaxis upon 
challenge with antigen if injected with serum from mice immunized 
with BSA in CFA/IFA (Supplemental Figure 1B).
ASA was not altered in Fcer1a/Fcer2a–double-deficient (FcεRI/II–/–) 
or in Fcgr3a-deficient (FcγRIIIA–/–) mice compared with WT 
mice (Figure 1A). Unexpectedly, ASA was also unaltered in FcγRI/
FcγRIIB/FcγRIIIA/FcεRI/FcεRII–/– (5KO) mice (Figure 1B and Sup-
plemental Table 1). 5KO mice lack all IgE and IgG receptors except 
the activating IgG2 receptor FcγRIV (17). Immunizations did not 
significantly modify the expression of FcγRIV (Supplemental Fig-
ure 1C). Anti-FcγRIV blocking mAbs abolished ASA in 5KO mice 
(Figure 1C). FcγRIV can therefore trigger anaphylaxis.
Neutrophils mediate FcγRIV-dependent ASA and secrete PAF. FcγRIV 
is expressed by monocytes/macrophages and neutrophils (17, 18), 
but not by basophils, mast cells, and eosinophils (Figure 1D). 
Monocytes and macrophages can be depleted by injecting toxic 
liposomes in vivo (19). Both control and toxic liposomes had the 
same effect on ASA, reducing ASA-associated mortality without 
altering ASA-associated temperature drop (Figure 1E). Toxic lipo-
somes, but not control liposomes, however, depleted monocytes 
(example shown in Supplemental Figure 1D). Depletion of 
monocytes/macrophages induced by toxic liposomes, therefore, 
did not alter ASA (Figure 1E). Supporting this result, ASA was 
unaffected in 5KO mice injected with gadolinium, which inhib-
its monocyte/macrophage function (Supplemental Figure 1E). 
Monocyte/macrophages are therefore not mandatory for ASA 
in 5KO mice. Noticeably, ASA-associated temperature drop and 
mortality were abrogated by neutrophil depletion in 5KO mice 
(Figure 1F). Anti-Gr1 injections depleted neutrophils, but did not 
reduce basophil numbers (Supplemental Figure 2, A and B). ASA 
was restored within 7 days in neutrophil-depleted mice, and it was 
correlated with blood neutrophil recovery (Figure 1G). Neutro-
phils, but not monocytes/macrophages, are therefore required for 
FcγRIV-dependent ASA. Importantly, purified bone marrow neu-
trophils from 5KO mice, but not from FcRγ–/– mice, restored ASA-
associated temperature drop in BSA-immunized FcRγ–/– recipients 
(Figure 2A). Neutrophils are therefore necessary and sufficient for 
FcγRIV-dependent ASA. Mediators released and/or secreted by 
activated neutrophils should therefore be responsible for the ana-
phylactic shock observed. Among them, PAF (20–22) was shown to 
mimic anaphylaxis when injected in mice (11). We detected PAF in 
the supernatant of neutrophils purified from 5KO, but not from 
FcRγ–/–, mice stimulated with IgG2b-IC in vitro. Anti-FcγRIV block-
ing mAbs abrogated PAF production by neutrophils from 5KO 
mice (Figure 2B). PAF may therefore be responsible for FcγRIV-
induced ASA in 5KO mice.
Neutrophils are immediately and systemically activated during active 
anaphylaxis. Upon activation, blood neutrophils release granules 
that contain mediators and enzymes, including myeloperoxidase 
(MPO). MPO can be released within minutes by activated neu-
trophils (data not shown and ref. 20) and, under inflammatory 
conditions, by monocytes/macrophages (23). MPO can oxidize 
luminol, and oxidized luminol emits luminescence. Lumines-
cence could, indeed, be detected in vivo in WT, but not in Mpo–/–, 
mice injected with luminol and challenged with PMA or LPS 
(24). Immunized, but not naive, 5KO mice exhibited a massive, 
systemic luminescence emission following antigen challenge 
and luminol injection (Figure 2C and Supplemental Figure 2C). 
Luminescence was detectable within minutes after antigen chal-
lenge and lasted for at least 20 minutes (Figure 2D and Supple-
mental Figure 2D). These results suggest that neutrophils are 
systemically activated within minutes in ASA.
FcγRIV, neutrophils, and PAF also contribute to PSA. We investigated 
whether neutrophil depletion or FcγRIV blocking, which both 
affect ASA, may also affect an IgG-induced PSA in immunodefi-
cient Rag2–/– 5KO mice. These mice, indeed, lack endogenous IgG 
that might compete with IC for FcγRIV binding. FcγRIV is indeed 
a high-affinity IgG receptor (17). An i.v. injection of monoclonal 
IgG2b-IC induced a significant, although nonlethal, temperature 
drop in Rag2–/– 5KO mice, but not in Rag2–/–FcRγ–/– mice (Figure 3A). 
FcγRIV blockade or neutrophil depletion abolished monoclonal 
IgG2b-induced PSA in Rag2–/– 5KO mice (Figure 3B). FcγRIV can 
therefore induce IgG2b-induced PSA that depends on neutrophils. 
Immunocompetent 5KO mice also developed IgG2b-induced PSA 
(data not shown). Because neutrophils from 5KO mice secrete PAF 
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Figure 1
Neutrophils mediate FcγRIV-dependent active anaphylaxis. Indicated mice were immunized and challenged with BSA. Central temperatures 
and survival rates were monitored. (A) ASA in WT (n = 4), FcγRIIIA–/– (n = 5), and FcεRI/II–/– (n = 4) mice. (B) ASA in WT (n = 9) and 5KO mice 
(n = 7). (C) ASA in 5KO mice injected with anti-FcγRIV mAbs (n = 10) or isotype control (n = 11) before BSA challenge. (D) Representative 
expression of FcγRIV on mouse blood and peritoneal cells: B cells (CD19+), T cells (CD4+), monocytes (mono.) (CD11b+Gr1–), neutrophils (neu-
tro.) (CD11b+Gr1+), basophils (baso.) (IgE+DX5+), eosinophils (eosino.) (Gr1+SiglecF+), macrophages (macro.) (CD11b+Gr1–), and mast cells 
(IgE+CD117+). (E and F) ASA in 5KO mice injected with (E) PBS liposomes (lipo.) (n = 7) or clodronate liposomes (n = 8), (F) anti-Gr1 mAbs 
(n = 8) or isotype (iso.) control (n = 9) before BSA challenge. Data are a compilation of 2 experiments. Note that both PBS and clodronate 
liposome injections inhibited ASA-associated mortality. (G) Immunized 5KO mice were injected with anti-Gr1 mAbs or isotype control on day 
0, challenged with BSA on day +1, retroorbitally bled on days +2 and +6, but otherwise left untouched until rechallenged with BSA on day +7. 
Upper panel: representative density plots of blood leukocytes stained as indicated. Percentages of Gr1hiCD11bhi cells (neutrophils) are indicated. 
Lower panel: ASA in immunized 5KO mice at day +7 after depletion (Iso, n = 3; anti-Gr1, n = 4). (A–C and E–G) Data are represented as mean 
± SEM. (A–F) Data are representative from at least 2 independent experiments (A, 2; B, 5; C, 4; D, 3; E, 2; and F, 4 experiments). ***P < 0.001. 
X’s represent mortality in the 100% experimental group.
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when stimulated in vitro with IgG2b-IC (Figure 2B), we measured 
PAF in the plasma of 5KO mice undergoing neutrophil-dependent 
IgG2b-induced PSA. We detected elevated PAF levels in the plasma 
of challenged, but not in nonchallenged (no detectable PAF; not 
shown), 5KO mice (Figure 3C). FcγRIV blockade abolished the 
increase in circulating PAF levels. Elevated PAF levels in plasma 
therefore correlate with FcγRIV-triggered, neutrophil-dependent 
PSA. Surprisingly, FcγRIV blockade or neutrophil depletion abol-
ished monoclonal IgG2b-induced PSA in WT mice also (Figure 3D). 
FcγRIV is therefore responsible for IgG2b-induced neutrophil-
dependent PSA in WT mice.
A nonlethal PSA could also be observed in Rag2–/– 5KO mice 
injected with IC made of GPI and K/BxN serum (GPI/anti-GPI-
induced PSA) (Figure 3E), which contains polyclonal IgG1 and 
IgG2 anti-GPI antibodies (25, 26). Neutrophil depletion abolished 
this GPI/anti-GPI–induced PSA in Rag2–/– 5KO mice (Figure 3F). 
As expected, FcγRIV blockade only slightly reduced GPI/anti-GPI–
induced PSA in WT mice. Surprisingly, however, the depletion of 
neutrophils, which express FcγRIV and FcγRIIIA, was sufficient 
to abolish GPI/anti-GPI–induced PSA in these mice (Figure 3G). 
Similar results were observed in 5KO mice (data not shown). 
Whereas basophils have been reported to mediate monoclonal 
IgG1-induced PSA (10), neutrophil depletion, but not basophil 
depletion, abolished GPI/anti-GPI–induced PSA in the same 
experiment (Figure 3H). Similarly, whereas mast cells have been 
reported to contribute to monoclonal IgG1-induced PSA (5), mast 
cell–deficient Wsh mice showed unaltered GPI/anti-GPI–induced 
PSA. Neutrophil depletion abolished GPI/anti-GPI–induced PSA 
in Wsh mice as efficiently as in WT mice, whereas basophil deple-
tion had no effect (Figure 3I). Together, these results demonstrate 
that neutrophils, but not mast cells or basophils, are mandatory 
for polyclonal IgG–induced PSA in nonimmunized WT mice.
FcγRIIIA and FcγRIV account for ASA in WT mice. We next inves-
tigated the contribution of activating Fc receptors to ASA in 
WT mice. WT mice express 1 activating IgE receptor, FcεRI, 
and 3 activating IgG receptors, FcγRI, FcγRIIIA, and FcγRIV. 
No anti-FcεRI– or anti-FcγRI–blocking antibodies are avail-
able. The recently described (27) mAb 275003, which is specific 
for FcγRIIIA (Figure 4A and Supplemental Figure 3, A and B), 
and which can block the binding of IgG-IC to FcγRIIIA in vitro 
(Supplemental Figure 3C), abolished FcγRIIIA-dependent (9) 
IgG-induced PSA (Figure 4B). FcγRIIIA blockade also signifi-
cantly reduced ASA-associated temperature drop and mortality 
in WT mice (Figure 4, C and D). FcγRIV blockade reduced ASA-
associated temperature drop similarly to FcγRIIIA blockade, 
but reduced mortality less efficiently (Figure 4D). Concomitant 
Figure 2
Neutrophil transfer restores ASA, and neutrophils are immediately and systemically activated during ASA. (A) BSA-immunized FcRγ–/– mice 
were injected i.v. with neutrophils from FcRγ–/– mice (n = 4) or from 5KO mice (n = 5), challenged with BSA, and central temperatures measured. 
Statistical differences are indicated for each time point if significant. Note that no mortality was observed during this experiment. (B) Purified bone 
marrow neutrophils from 5KO or FcRγ–/– mice were stimulated with antigen alone (Ag) or with IgG IC, or preincubated with anti-FcγRIV Abs before 
stimulation with IC (IC plus anti-FcγRIV), and PAF concentration was determined in culture supernatants. Means of triplicates are represented. 
(C) Naive or BSA-immunized 5KO mice were anesthetized, challenged with BSA (t = 0), and injected with luminol (t = 5 minutes). Representative 
images show color-coded maps of photon flux superimposed on black and white photographs of mice (15- to 20-minute time frame after challenge) 
(n = 2). (D) Time course of photon fluxes from naive and BSA-immunized 5KO mice (n = 3) following BSA challenge (t = 0). (A and D) Data are 
represented as mean ± SEM. (C and D) Data are representative from 2 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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FcγRIIIA and FcγRIV blockade, however, were necessary to abol-
ish ASA in WT mice (Figure 4, D and E). FcγRIIIA and FcγRIV 
therefore account for ASA in WT mice.
Neutrophils and basophils contribute to ASA in WT mice. FcγRIIIA 
and FcγRIV are both expressed by neutrophils, monocytes, and 
macrophages. FcγRIIIA, but not FcγRIV, is expressed also on 
basophils, eosinophils, and mast cells (Figure 5A and Figure 1D). 
All these cell types can potentially contribute to ASA. Inhibition 
of monocyte/macrophages (Figure 5B) or depletion of eosino-
phils (Supplemental Figure 3D) did not affect ASA in WT mice. 
Importantly, neutrophil depletion reduced temperature drop 
and prevented ASA-associated death in WT mice (Figure 5C). 
Basophil depletion (example shown in Supplemental Figure 
3E) had no effect unless neutrophils were also depleted, sug-
gesting a dominant role for neutrophils in ASA (Figure 5C). 
Similar results were obtained in mast cell–deficient Wsh mice 
(Figure 5D) and in FcγRIIIA–/– mice that express no activating 
FcγRs on mast cells and basophils (Figure 5E). ASA in WT mice 
is therefore unaffected by a deficiency in a single cell popula-
tion, except that of neutrophils.
We observed that the proportion of blood neutrophils significantly 
increased following immunizations with antigen in CFA/IFA. Neu-
trophilia is not specific to this adjuvant, as it was also observed fol-
lowing immunization with alum or with alum plus Pertussis toxin 
(Figure 6A). This observation could possibly explain the dominant 
contribution of neutrophils to ASA following CFA/IFA immuniza-
tions. To test this hypothesis, we delayed the antigenic challenge for 
several weeks until neutrophil numbers dropped back to baseline. Six 
weeks after immunization, neutrophil numbers in 5KO mice immu-
nized with BSA in CFA/IFA were comparable to neutrophil numbers 
in naive mice (Figure 6B), while the levels of anti-BSA antibodies in 
the serum remained high (Figure 6C). When challenged with BSA, 
these 5KO mice developed ASA, as expected, and ASA-associated 
temperature drop and mortality were both dependent on neutrophils 
Figure 3
Neutrophils and FcγRIV account for IgG2b-IC induced PSA in WT mice, and neutrophils account for GPI/anti-GPI–PSA in WT mice. (A, B, and 
D) Indicated mice were injected with preformed IgG2b-IC (monoclonal IgG2b anti-DNP mAb plus DNP-HSA), and central temperatures were 
monitored (A, n = 4; B, n = 3; D, n = 3). (C) 5KO mice were preinjected or not with anti-FcγRIV Abs before challenge with IgG2b-IC. Plasma was 
collected 20 minutes after challenge, and PAF concentration was determined. Means of triplicates are represented. (E–I) Mice were injected with 
indicated mAbs or isotype controls before injection of preformed polyclonal IgG-IC (GPI/anti-GPI). Central temperatures were monitored (E, n = 4; 
F, n = 4; G, n = 5; H, n = 4; I, n = 4). (G) Statistical differences between the untreated and the anti-Gr1–treated groups are indicated for each time 
point if significant. (A–I) Data are represented as mean ± SEM. (A, B, and D–I) Data are representative of 2 independent experiments. Note that 
no mortality was observed in all these experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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(Figure 6D). The dominant role for neutrophils in ASA is therefore 
not due to higher neutrophil numbers in immunized mice.
PAF mediates neutrophil-dependent ASA. Because neutrophils play 
a dominant role in ASA in 5KO mice and in WT mice, because 
neutrophils secrete PAF in vitro (Figure 2B), and because PAF con-
centration is elevated in plasma during neutrophil-dependent PSA 
(Figure 3C), we analyzed the contribution of PAF to ASA in 5KO 
and in WT mice. Two PAF-R antagonists (Figure 7A), but not a his-
tamine receptor-1 antagonist (Figure 7B), markedly reduced ASA 
in 5KO mice. PAF-R antagonists also abolished ASA-associated 
death and inhibited temperature drop in WT mice, whereas hista-
mine receptor-1 antagonist had a much milder effect (Figure 7C). 
Figure 4
FcγRIIIA and FcγRIV account for ASA in WT mice. (A) Representative density plots of CD11b and FcγRIIIA expression on blood leukocytes from 
WT or FcγRIIIA–/– mice. (B) FcγRIIB–/– mice or FcγRIIB/IIIA–/– double-deficient mice were injected with anti-FcγRIIIA mAb or not before injection 
with IgG1-IC (n = 3). Central temperatures were monitored. Statistical differences between groups treated with 0 and 25 μg and those treated 
with 0 and 50 μg are indicated under and over the horizontal axis, respectively, for each time point if significant. (C–E) Indicated mice were 
immunized and challenged with BSA. Central temperatures and survival rates were monitored. (C) ASA in WT mice injected with anti-FcγRIIIA 
(n = 5) or vehicle (n = 3) before BSA challenge. (D) ASA in WT mice injected with vehicle (n = 8), anti-FcγRIIIA mAbs (n = 7), anti-FcγRIV mAbs 
(n = 8), or both mAbs (n = 7). Statistical differences between the vehicle-treated group and each experimental group are indicated at the right 
end of each curve. (E) ASA in WT mice injected with indicated mAbs before BSA challenge (n = 4). (A–E) Data are represented as mean ± SEM 
and are representative of 2 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. X’s represent 100% mortality in the vehicle group.
research article
1490	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 121   Number 4   April 2011
PAF production requires cytosolic phospholipase A2 (cPLA2) (28–
30). ASA was strongly inhibited in cPLA2-deficient mice (Figure 7D). 
PAF may therefore account for neutrophil-dependent ASA in 5KO 
mice and contributes to ASA in WT mice.
Human neutrophils restore ASA in FcRγ–/– mice. Like murine neu-
trophils (Supplemental Figure 4A), human neutrophils express 
FcRs. The only activating FcRs expressed by neutrophils from 
normal donors are FcγRIIA (Figure 8A). Human neutrophils, 
Figure 5
Neutrophils and basophils contribute to active anaphylaxis in WT mice. (A) Representative histogram plots of FcγRIIIA expression in WT mice 
on cell populations identified as in Figure 1D. (B–E) Indicated mice were immunized against BSA and challenged with BSA. Central tempera-
tures and survival rates were monitored. (B) WT mice were injected with gadolinium or vehicle before BSA challenge (n = 4). (C) WT mice were 
injected with anti-Gr1, anti-CD200R3, anti-Gr1 plus anti-CD200R3 mAbs (n = 4), or isotype controls (n = 5) before BSA challenge. Survival of 
the isotype-treated group is statistically different from the anti-Gr1 and from the anti-Gr1 plus anti-CD200R3 groups (P < 0.05), but not from the 
anti-CD200R3 group. (D) Wsh mice were injected with anti-CD200R3 (top: n = 3; bottom: n = 4), anti-Gr1 (top: n = 4), anti-Gr1 plus anti-CD200R3 
(top: n = 5; bottom: n = 4) mAbs, or isotype controls (top: n = 4; bottom: n = 3) before BSA challenge. (E) FcγRIIIA–/– mice injected with anti-Gr1 
mAbs or isotype control before BSA challenge (n = 5). (B–E) Data are represented as mean ± SEM. (A–E) Data are representative of 2 inde-
pendent experiments. **P < 0.01. X’s represent 100% mortality in the experimental group.
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indeed, do not express FcγRI, FcεRI, or FcγRIIIA. They, however, 
express the GPI-anchored FcγRIIIB (31, 32). FcγRIIA, but not 
FcγRIIIB, could bind IC made with mouse IgG1, IgG2a, or IgG2b 
(Figure 8B). Human neutrophils could be activated in vitro 
by IC made with mouse polyclonal IgG (Figure 8C) or mouse 
monoclonal IgG1 or IgG2b (Supplemental Figure 4B), as could 
murine neutrophils from WT and 5KO, but not from FcRγ–/–, 
mice (Supplemental Figure 4C). Neutrophils purified from nor-
mal human donors could restore ASA when injected i.v. into 
immunized FcRγ–/– mice prior to antigen challenge (Figure 8, 
D–F). Importantly, the same neutrophils purified from indi-
vidual donors induced no anaphylaxis upon antigen challenge 
in nonimmunized mice (Figure 8, E and F). The intensity of the 
shock was proportional to the number of human neutrophils 
transferred into FcRγ–/– mice. Human neutrophils can therefore 
substitute for murine neutrophils in ASA.
Discussion
We show here that IgG antibodies, activating FcγRs, neutrophils, 
and PAF are the main players in ASA, whereas IgE antibodies (12), 
FcεRI (5), mast cells (5, 13), and histamine do not play a major role.
Several cell types have been involved in anaphylaxis; among 
them are mast cells and basophils. We demonstrate that neutro-
phils are not only sufficient to induce ASA, but play a dominant 
role. Indeed, neutrophil depletion, but not basophil depletion, 
eosinophil depletion, monocyte/macrophage inhibition or mast 
cell deficiency, abrogated ASA-associated death, and reduced tem-
perature drop in WT mice. Importantly, transfer of mouse neu-
Figure 6
High neutrophil numbers are not responsible for the predominant contribution of neutrophils to ASA. (A) WT mice were left untreated (naive, 
n = 7) or were injected 3 times with BSA in the indicated adjuvant (CFA/IFA, n = 5; alum plus PTX, n = 4; alum, n = 8) or 1 time only with BSA 
in alum (n = 10). The proportion of granulocytes among wbc and the absolute granulocyte counts in blood 7 days after the last immunization is 
represented as individual results and mean. PTX, pertussis toxin. (B and C) Absolute granulocyte counts (B) and anti-BSA antibody levels (C) 
in blood of 5KO mice over time after the last immunization (t = 0) in CFA/IFA (n = 8). (D) Mice from B and C were injected with indicated mAbs 
and challenged with BSA 7 weeks after the last immunization (n = 4). Statistical significance is indicated. (B–D) Data are represented as mean 
± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
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trophils expressing FcγRIV, but not of neutrophils expressing no 
activating FcγRs, restored ASA in FcRγ–/– mice. Neutrophil activa-
tion could be visualized in vivo within minutes in mice undergo-
ing ASA. Although monocytes/macrophages were reported to be 
involved in a model of anaphylaxis induced by an i.v. injection of 
goat IgG in mice immunized with goat IgG anti-mouse IgD (33), 
we could not detect any role for monocytes/macrophages in ASA 
in mice immunized with antigen in CFA/IFA. The depletion of 
eosinophils did not impair ASA either. Basophil depletion, which 
did not affect ASA by itself, further reduced ASA when combined 
with neutrophil depletion. Basophils therefore contribute to 
ASA together with neutrophils, but neutrophils play a dominant 
role. One possible explanation is that neutrophils are much more 
numerous than basophils in blood.
Noticeably, we observed neutrophilia following immunization 
of mice with antigen in CFA/IFA. We excluded that neutrophilia 
accounted for the dominant contribution of neutrophils to ASA 
by delaying antigen challenge until neutrophil numbers in immu-
nized mice were comparable to those in naive mice. Under these 
conditions, neutrophils were also mandatory for ASA in 5KO 
mice. We found that neutrophils also predominantly contributed 
to IgG-induced PSA (whether induced by monoclonal IgG2b-IC 
or polyclonal-IC) in nonimmunized WT mice that have normal 
numbers of neutrophils. We also observed neutrophilia following 
immunizations with alum or with alum plus Pertussis toxin. In pre-
liminary experiments, neither neutrophil depletion nor basophil 
depletion significantly reduced temperature drop, but a depletion 
of both cell types abolished ASA in mice immunized with anti-
gen in alum (our unpublished observations). Taken together, our 
results demonstrate that neutrophils contribute to anaphylactic 
shock in 2 models of ASA, i.e., following immunization in CFA/
IFA or in alum, and in 2 models of PSA, i.e., induced by polyclonal 
IgG-IC or monoclonal IgG2b-IC.
Two mediators, PAF and histamine, were found to play a critical 
role in experimental anaphylaxis. Mast cells, basophils and, appar-
ently, neutrophils (34) can release histamine. Histamine accounts 
for IgE-induced PSA but not for IgG1-induced PSA, whereas PAF 
accounts for IgG1-induced PSA but not IgE-induced PSA (10). 
We found that PAF has a dominant role in ASA. Indeed, PAF-R 
antagonists, but not histamine receptor H1 antagonists, markedly 
reduced temperature drop and prevented death in ASA in mice 
immunized with antigen in CFA/IFA. In agreement with these 
results, ASA-associated heart rate and arterial pressure reduction 
were strongly impaired in PAF-R–deficient mice (15), suggesting 
that ASA-associated temperature drop and mortality may also be 
inhibited in these mice. Indirectly supporting this assumption, 
Figure 7
PAF mediates neutrophil-dependent 
active anaphylaxis. Indicated mice 
were immunized and challenged 
with BSA. Central temperatures and 
survival rates were monitored. (A 
and B) ASA in 5KO mice injected 
(A) with vehicle or indicated PAF-R 
antagonists (n = 4) or (B) with vehi-
cle or cyproheptadine (n = 4) before 
BSA challenge. (C) ASA in WT mice 
injected with ABT-491, cyprohepta-
dine, or vehicle before BSA challenge 
(n = 3). (D) ASA in cPla2–/– mice (n = 5) 
or heterozygous littermate controls 
(n = 8). (A–D) Data are represented 
as mean ± SEM and are represen-
tative of 2 independent experiments. 
X’s represent 100% mortality in the 
experimental group.
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ASA was virtually abrogated in cPLA2-deficient mice (our results 
and ref. 29), which cannot generate several lipid-derived mediators, 
including PAF. Activated neutrophils (20, 22), monocytes/macro-
phages (35), and eosinophils (36) all produce PAF, but neutro-
phils were reported to be major producers (21). We found, indeed, 
that neutrophils secrete PAF when stimulated by IgG2b-IC, but 
we also found elevated PAF levels in plasma of mice undergoing 
neutrophil-dependent PSA. Together our results suggest that 
PAF released upon neutrophil activation during ASA and PSA is 
responsible for anaphylactic shock.
ASA depends on activating receptors (5) that associate with and 
whose expression and signaling depend on FcRγ. These are FcγRI, 
FcγRIIIA, FcγRIV, and FcεRI (37). ASA was reported in IgE-defi-
cient mice (12), and we observed that it was comparable in WT 
and FcεRI-deficient mice. Similarly, the deletion of FcεRI did not 
affect ASA in mice immunized with antigen in alum (5, 38). While 
blocking either FcγRIIIA or FcγRIV reduced ASA, blocking both 
receptors abrogated ASA in WT mice. IgG antibodies seem there-
fore more important than IgE antibodies in ASA following immu-
nization in CFA/IFA. FcγRIV contributed to ASA in WT mice, 
and it was necessary and sufficient to induce ASA in 5KO mice. 
Although FcγRIV are expressed by neutrophils and by monocytes/
macrophages (18), only neutrophil FcγRIV accounts for ASA in 
5KO mice. A single activating FcγR on a single cell population is 
therefore sufficient to induce ASA. Our results demonstrate that 
FcγRIIIA or FcγRIV is responsible for ASA following CFA/IFA 
immunizations, and that each could substitute for the other to 
induce ASA, provided that IgG2 antibodies are produced.
That IgG1 can induce anaphylaxis was demonstrated by PSA. 
The only activating FcR having an affinity for IgG1 is FcγRIIIA 
(17, 18). Depletion of basophils using specific mAbs abrogated 
IgG1-induced PSA (10), although mast cells and neutrophils also 
express FcγRIIIA. A model of basophil-deficient mice, however, 
challenges this result (14). Mast cells are necessary for IgE-induced 
PSA, although basophils also express FcεRI. Noticeably, IgE-
induced PSA was abolished in 5KO mice (data not shown). FcγRIV 
that can bind IgE with a low affinity (17) is therefore insufficient 
to trigger this reaction. IgG1 is the predominant antibody sub-
class following immunization in alum, but also in CFA/IFA. IgG1 
antibodies are likely to act as the main players in ASA by engag-
ing FcγRIIIA. BSA immunizations in alum induced specific IgG1, 
but not specific IgG2 (Supplemental Figure 4D), indicating that 
FcγRIIIA, but not FcγRIV, were engaged during ASA following this 
immunization protocol. Supporting this conclusion, FcγRIV was 
not sufficient to induce ASA in 5KO mice following immunization 
in alum (Supplemental Figure 4E).
Figure 8
Human neutrophils restore anaphylaxis 
in resistant mice. (A) Representative 
histogram plots of human FcR expres-
sion on purified human neutrophils. (B) 
Histograms show the binding of indicat-
ed IgG IC or anti-FLAG mAbs (FLAG) 
to indicated FLAG-tagged FcγR+ CHO 
transfectants. Both polymorphic vari-
ants of human FcγRIIA at position 131 
are used and represented. All human 
FcγRIIIB variants (NA1, NA2, and SH) 
gave identical results; only variant 
NA1 is represented. (C) Expression of 
CD62L on purified human neutrophils 
from healthy donors incubated with 
GPI/anti-GPI IC (n = 5) and controls. 
Data represent individual results and 
means. (D) FcRγ–/– mice were immu-
nized with BSA, injected or not with 
2 × 106 human neutrophils, challenged 
with BSA, and central temperatures 
monitored (n = 3). Data are represented 
as mean ± SEM. Statistical differences 
are indicated. (E and F) Purified human 
neutrophils originating from 1 healthy 
donor were divided equally in 2 frac-
tions. One fraction was injected into a 
naive (open symbols) and 1 fraction into 
a BSA-immunized FcRγ–/– mice (closed 
symbols) at (E) 7.5 × 105 neutrophils 
per mouse (n = 3) or (F) 1.5 × 106 
neutrophils per mouse (n = 2). Mice 
were subsequently challenged with 
BSA and central temperatures were 
monitored. Each symbol corresponds 
to the pair of mice that received neutro-
phils from 1 specific donor. *P < 0.05; 
**P < 0.01; ***P < 0.001.
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We found, however, that not only IgG1, but also IgG2, antibod-
ies could induce PSA. IgG2-induced PSA could develop in 5KO 
mice, and neutrophils contributed to the shock. IgG2 can there-
fore contribute to anaphylaxis. IgG2-IC that may form in vivo 
upon antigen challenge following immunization in CFA/IFA may 
be responsible for the predominant role of neutrophils as IgG2 
IC can engage FcγRIV (but also FcγRIIIA) on these cells. In the 
absence of IgG2 antibodies, as in ASA following immunization 
with antigen in alum, IgG1-IC may trigger FcγRIIIA-expressing 
basophils and neutrophils. It follows that basophils contribute to 
ASA and to PSA when IgG1-IC are present (this report and ref. 
10), but also other cells (14), among which are neutrophils. Our 
results indicating that neutrophils are mandatory for polyclonal 
IgG-induced PSA differ from previous reports implicating mast 
cells (5) and basophils (10) in IgG1-induced PSA. They are, howev-
er, not contradictory. Indeed, monoclonal IgG1-IC can selectively 
engage FcγRIIIA, while IgG-IC made of IgG1 and IgG2 isotypes 
will engage both FcγRIIIA and FcγRIV, to induce PSA. FcR-express-
ing cells involved in each type of PSA may therefore be different. 
Taken together, these data suggest that IgE, IgG1, and IgG2 can all 
induce anaphylaxis when engaging FcεRI, FcγRIIIA, and FcγRIV on 
mast cells, basophils, and neutrophils, respectively. Although like-
ly, it was not formally demonstrated that FcεRI or FcγRIIIA alone 
could induce ASA. Using the 5KO model, we provide evidence that 
FcγRIV alone can. Because FcγRIV is a receptor for IgG2, but not 
for IgG1, and is expressed by neutrophils, but not by basophils 
or mast cells, we are able to demonstrate here a role for the most 
unexpected antibody, receptor, and cell type in ASA in mice.
Human anaphylaxis is essentially active. IgG1 is the most abun-
dant IgG subclass in human plasma, and the majority of antibod-
ies raised by vaccinations (generally in alum) belong to this sub-
class. Human IgG1 binds to all activating human FcγRs (39). Both 
specific IgE and IgG antibodies are found in the serum of aller-
gic patients, but the relative concentration of the various classes 
is poorly known and rarely investigated. FcγRIV has no human 
ortholog, and FcγRIIIA are not expressed by human neutrophils, 
basophils, and mast cells (40). These 3 cell types, nevertheless, 
express activating Fc receptors. All of them express another activat-
ing IgG receptor, FcγRIIA. Mast cells and basophils also express the 
high-affinity IgE receptor FcεRI in normal individuals as well as 
neutrophils in atopic patients (41). These 3 cell types can produce 
PAF upon activation, especially neutrophils (21). PAF could play an 
important role in human anaphylaxis. Indeed, plasma PAF concen-
tration has been correlated with the severity of shocks in patients 
(42). Although the cellular source of PAF in human anaphylaxis 
was not identified, the above-mentioned results endow neutro-
phils with a critical role. Supporting this assumption, IgG-IC 
could activate human neutrophils in vitro, and a transfer of human 
neutrophils restored ASA in FcRγ-deficient mice.
In conclusion, we demonstrate here a previously unexpected role 
of neutrophils in anaphylaxis. An IgG2-induced, FcγRIV-depen-
dent, PAF-mediated active anaphylaxis, contingent on neutro-
phils, could be unraveled using immunized multiple FcR-deficient 
mice. IgG-induced, FcγR-dependent, PAF-mediated ASA was also 
observed in WT mice, to which neutrophils contributed. Anaphy-
laxis induction is therefore a property of neutrophils, which is not 
trivial considering that neutrophils are the most numerous cells 
among blood leukocytes in humans. This may have important 
therapeutic consequences if indeed neutrophils can induce IgG-
dependent anaphylactic reactions in humans.
Methods
Mice. 5KO (N6 B6) mice have been described (17). cPla2–/– mice (129/B6) 
were provided by J. Bonventre (Brigham and Women’s Hospital, Harvard 
Institutes of Medicine, Boston, Massachusetts, USA); KRN transgenic 
mice were provided by D. Mathis and C. Benoist (Harvard Medical 
School, Boston, Massachusetts, USA) and the Institut de Génétique et de 
Biologie Moleculaire et Cellulaire (Illkrich, France). WT C57BL/6J and 
NOD mice were purchased from Charles River, and Wsh/Wsh, FcγRIIIA–/– 
and FcRγ–/– C57BL/6J mice from Jackson Laboratories. Rag2–/– mice were 
used to generate Rag2–/– 5KO and Rag2–/–FcRγ–/– mice by intercrosses. All 
mouse protocols were approved by the Animal Care and Use Committees 
of Paris, Île de France, France.
Antibodies, reagents, and cells. PBS- and clodronate-liposomes were prepared 
as previously described (19). Alum hydroxide gel, pertussis toxin, BSA, 
DNP-HSA, rabbit GPI, gadolinium(III) chloride, CFA and IFA, CV-3988, 
ABT-491, cyproheptadine, and luminol were obtained from Sigma-Aldrich; 
anti-mouse CD11b, CD4, CD19, Gr1, SiglecF, CD117, IgE, and anti-
human FcγRI, FcγRIII, CD62L were from BD Biosciences; anti-mouse DX5, 
mFcεRI, and anti-hFcεRI were from eBioscience; anti-mFcγRI (290322) 
and mFcγRIIIA (275003) were from R&D Systems; anti–hFcγRIIA mAbs 
(IV.3) were from StemCell Technologies; mouse IgG3 anti-DNP were from 
Serotec; and the MPO ELISA kit was from HyCult Biotech. The hybrid-
omas producing mAbs anti-mFcγRIV (9E9) were provided by J.V. Ravetch 
(Rockefeller University, New York, New York, USA); anti-Gr1 (RB6-8C5) 
was provided by R. Coffman (DNAX Research Institute, Palo Alto, Califor-
nia, USA); mIgG2a anti-platelet (6A6) was provided by R. Good (University 
of South Florida College of Medicine, Tampa, Florida, USA); and mIgG1 
and mIgG2b anti-DNP was provided by B. Heyman (Uppsala Universitet, 
Uppsala, Sweden). Purified mAbs anti-hFcγRIIB/C (GB3) were provided 
by U. Jacob (SuppreMol GmbH); anti-CCR3 was provided by J.J. Lee (Mayo 
Clinic, Scottsdale, Arizona, USA). Anti-CD200R3 (Ba103) was produced as 
described (10). CHO K1 cells stably transfected with FLAG-tagged mouse 
FcγRs (17) or human FLAG-tagged FcγRs (39) were cultured as described.
Flow cytometry analysis. Cells were stained with indicated fluorescently 
labeled mAbs for 30 minutes at 0°C.
IC binding. Mouse IC were preformed by incubating 10 μg/ml DNP16-
BSA-biotin with 15 μg/ml anti-DNP mAbs for 1 hour at 37°C. 2 × 105 cells, 
preincubated or not with indicated blocking mAbs, were incubated with IC 
for 2 hours at 4°C, which were detected using neutravidin-PE at 2 μg/ml 
for 30 minutes at 4°C.
ASA. 6- to 9-week-old male mice were used for ASA. They were injected 
i.p. at days 0, 14, and 28 with 200 μg BSA, either once in CFA and twice in 
IFA, or 3 times in alum, or 3 times in alum plus Pertussis toxin. BSA-specific 
IgG1 and IgG2a/b/c antibodies in serum were titered by ELISA at day 30. 
Briefly, BSA-coated plates were sequentially incubated with dilutions of 
serum, HRP-labeled anti-Ig isotype antibodies, and SIGMAFAST OPD 
solution. Internal negative (serum from naive C57BL/6J mice) and positive 
(pool of serum of BSA-immunized C57BL/6J mice) controls were added to 
all test plates to define a background value and a “value 1” in arbitrary units, 
respectively. High titers of IgG1 antibodies were found in mice immunized 
using either CFA/IFA or alum immunization protocol. IgG2 antibodies were 
detected in mice immunized using CFA and IFA only. Absolute counts and 
proportions of granulocytes in peripheral mouse blood were determined 
using an ABC Vet automatic blood analyzer (Horiba ABX).
Mice with comparable antibody titers were challenged i.v. with 500 μg BSA 
(unless otherwise specified) 10 days after the last immunization. Note that 
the amount of antigen that induced ASA (Supplemental Figure 5A) was sim-
ilar to that reported to be required for IgG-induced PSA (43). Central tem-
perature was monitored using a digital thermometer (YSI), and time of death 
was recorded. Except in Figure 1, E and F, and in Figure 2A, data presented in 
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each figure correspond to 1 representative experiment. Supplemental Table 1 
lists the total number of mice that were used for indicated experimental con-
ditions, their grades of anaphylactic shock, and the mortality rate.
PSA. Mice were injected i.v. with preformed IC made of 20 μl K/BxN 
serum and 50 μg GPI (Figure 4B); 500 μg IgG2b mAb anti-DNP and 
200 μg DNP-HSA (Figure 3, A, B, and D); and IC made of 100 μl K/BxN 
serum and 40 μg GPI (Figure 3, E–I). Alternatively (Supplemental Figure 1B), 
500 μl of serum from BSA-immunized mice collected on day 30 was inject-
ed i.v. into naive mice and mice were challenged 3 hours later with an i.v. 
injection of 500 μg BSA. Central body temperature was recorded using a 
digital thermometer (YSI).
Experimental immune thrombocytopenia. Blood samples were taken retroor-
bitally before and at indicated time points after the i.v. injection of 5 μg of 
anti-platelet mAb 6A6. Platelet counts were determined using an ABC Vet 
automatic blood analyzer (Horiba ABX).
In vivo blocking and depletion. 200 μg/mouse of anti-FcγRIV mAbs were inject-
ed i.v. 30 minutes before challenge. 50 μg/mouse of anti-FcγRIIIA mAbs, 
2.1 mg/mouse of PBS- or clodronate-liposomes, 300 μg/mouse of anti-Gr1 or 
anti-CCR3 mAbs, and 30 μg/mouse of anti-CD200R3 mAbs or 1 mg/mouse 
of gadolinium were injected 24 hours before challenge. 66 μg/mouse 
CV-3988, 25 μg/mouse ABT-49, or 50 μg/mouse cyproheptadine was 
injected i.v. 10, 20, or i.p. 30 minutes before challenge, respectively.
Depletion of cell populations was ascertained for specificity of the 
depletion using flow cytometry on blood samples taken during or after 
the experiment (as represented in the figures, or in examples shown in Sup-
plemental Figure 1D, Supplemental Figure 2, A and B, and Supplemental 
Figure 3, D and E). Depletion of specific cell populations or efficiency of 
blocking antibodies was also controlled using the macrophage-dependent 
experimental immune thrombocytopenia (ITP) model: ITP in 5KO mice 
was inhibited by FcγRIV blockade (Supplemental Figure 5B), as expected 
(18), was inhibited by monocyte/macrophage depletion using toxic lipo-
somes (Supplemental Figure 5C), as expected (44), and was unaltered by 
neutrophil depletion (Supplemental Figure 5D).
Bioluminescence imaging. Bioluminescence from depilated and anesthe-
tized mice injected i.p. with 15 mg/mouse luminol was acquired on an IVIS 
100 (Caliper Life Sciences) using 2–5 minute exposure times with medium 
binning. Average radiance (photons/seconds/cm2/surface radiance) and 
total photon flux of indicated regions of interest (Figure 2C) were calcu-
lated using Living Image software.
Purification, in vitro stimulation, and transfer of mouse neutrophils. For in vitro 
analysis, murine neutrophils were purified (>95% purity) from bone mar-
row suspensions using anti-Ly6G microbead kits (Miltenyi Biotec). 1.4 × 105 
neutrophils were challenged with plate-bound stimulants or PMA plus 
thapsigargin for 1 hour. CD62L expression was assessed by flow cytometry 
and MPO by ELISA on cell supernatants.
For in vivo transfer, neutrophils were recovered from bone marrow sus-
pensions following double-gradient centrifugation (Histopaque-1119, 
Ficoll-Paque PLUS: 50/50 v/v). 3 × 106 neutrophils were injected i.v. into 
BSA-immunized mice 20 minutes before challenge.
Measurement of PAF in vitro. Purified neutrophils (1 × 106 cells in 0.1 ml) were 
incubated on plate-bound DNP-HSA alone (Ag; at 10 μg/ml) or plate-bound 
DNP-HSA (at 10 μg/ml) plus anti-DNP IgG2b GORK (IC; at 100 μg/ml) in 
HBSS buffer supplemented with 1.26 mM CaCl2 and 0.9 mM MgCl2. When 
indicated, neutrophils were preincubated with 20 μg/ml of anti-FcγRIV mAbs. 
Culture supernatants were collected after 20 minutes at 37°C.
Measurement of PAF in vivo. 100 μl of plasma was collected from mice 
undergoing monoclonal IgG2b PSA (IC made of 1 mg IgG2b mAb anti-
DNP and 300 μg DNP-HSA) at t = 20 minutes following challenge. When 
indicated, mice were preinjected with 200 μg/ml of anti-FcγRIV Ab 30 min-
utes before challenge.
Culture supernatants or plasma were mixed 1:10 v/v in methanol, cen-
trifuged at 16,100 g for 10 minutes; supernatants were frozen at –20°C. 
After adding deuterized PAF (PAF-d4; Cayman Chemical) as an internal 
standard to supernatants, PAF-containing lipids were extracted with Oasis 
HLB solid phase extraction cartridge (10 mg/ml; Waters) as described (45). 
PAF was quantified using liquid chromatography-tandem mass spectrom-
etry on a TSQ Quantum Ultra mass spectrometer (Thermo Fisher Scien-
tific) that was operated in negative electrospray ionization. HPLC condi-
tions and mass spectrometry parameters were described previously (45). 
The selected reaction monitoring (SRM) modes was used to monitor 568.5 
to 59 m/z transitions for PAF and 572.5 to 59 m/z transitions for PAF-d4. 
Commercial PAF (Cayman Chemical) mixed with PAF-d4 was used to draw 
calibration curves, and data were processed using the Xcalibur 2.0 software 
(Thermo Fisher Scientific). PAF values of less than 5 pg should be consid-
ered under the lower detection limit (Figure 2B and Figure 3C).
Purification and transfer of human neutrophils. Human granulocytes were puri-
fied (>95% purity) from normal heparinized blood by double-gradient cen-
trifugation (Histopaque-1119, Ficoll-Paque Plus: 50/50 v/v) and using anti-
CD15 microbeads (Miltenyi Biotec). For transfer experiments, neutrophils 
were injected i.v. 15 minutes prior to BSA challenge. For in vitro analysis, 
2 × 105 neutrophils were stimulated for 1 hour at 37°C with 100 nM PMA or 
IC (30 μg/ml GPI and 1/100 dilution of KxB/N serum) or neutrophils with 
plate-bound IC (DNP-HSA and indicated mouse anti-DNP antibodies).
Statistics. Data were analyzed using 1-way ANOVA with Bonferroni’s 
post-test (Figure 6A, Figure 8C, and Supplemental Figure 4B) or 2-tailed 
Student’s t test (all other data). P < 0.05 was considered significant.
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